The article provides an overview of the literature data on key aspects of the treatment of gouty arthritis. Paying attention to the objectives and characteristics of dietary treatment, medication and physical therapy of gouty arthritis. Shows the recommended medications and combinations thereof in the treatment of gouty arthritis, tophi indications for surgical treatment. The methods of intensive patient education, which includes a belief in the need to change their lifestyle, smoking cessation and alcohol; the pursuit of the ideal body weight and dieting; information on the nature of the clinical manifestations of acute gouty arthritis and consequences of uncontrolled hyperuricemia; about the purposes and characteristics of the treatment of gout; methods of rapid relief of acute gouty arthritis, the side effects of drug therapy. The main therapeutic errors in the treatment of acute gout period. The review includes studies to analyze the effectiveness of various drugs for the treatment of gouty arthritis, the doctor described the tactics under certain comorbid conditions. The necessity of a proper understanding of all the issues of treatment and selection of the most appropriate drug for the individual patient with gout.

1. Барскова, В. Г. Рациональные подходы к лечению подагры (по материалам рекомендаций Европейской антиревматической лиги) / В. Г. Барскова // Современная ревматология. — 2008. — № 1. — С. 16—18.

2. Барскова, В. Г. Фебуксостат — новый препарат в терапии подагры / В. Г. Барскова, Е. В. Ильиных, Е. Л. Насонов // Научнопрактическая ревматология. — 2011. — № 2. — С. 52—58.

3. Барскова, В. Г. Что должен знать терапевт о ведении больного острым подагрическим артритом / В. Г. Барскова // Современная ревматология. — 2014. — № 3. — С. 84—87.

4. Ватутин, Н. Т. Диагностика, лечение и профилактика подаг­ ры: международные клинические рекомендации 2014 г / Н. Т. Ва­ тутин, А. С. Смирнова, Ю. П. Гриценко // Современная ревматоло­ гия. — 2015. — № 9. — С. 70—72.

5. Владимиров, С. А. Лечение хронической подагры: выбор противовоспалительной терапии / С. А. Владимиров, M. С. Ели­ сеев // Практическая медицина. — 2015. — № 3 (Т. 2). — С. 114—118.

6. Елисеев, М. С. Клинический опыт применения блокатора интерлейкина 1β канакинумаба у больных хронической тофусной подагрой: купирование артрита и профилактика обострений при назначении аллопуринола / М. С. Елисеев [и др.] // Современная ревматология. — 2015. — № 9. — С. 16—22.

7. Елисеев, М. С. Новые международные рекомендации по диагностике и лечению подагры: простые ответы на простые вопросы / М. С. Елисеев // Научно-практическая ревматология. — 2014. — № 52. — С. 141—146.

8. Ильина, А. Е. Опыт длительного применения Урисана у больных подагрой / А. Е. Ильина, В. Г. Барскова // Современная ревматология. — 2009. — № 2. — С. 53—55.

9. Ильина, А. Е. Применение урисана при подагре / А. Е. Ильина, В. Г. Барскова // Современная ревматология. — 2009. — № 1. — С. 49—50.

10. Михневич, Э. А. Подагра : учеб.-метод. пособие / Э. А. Мих­ невич. — Минск: БГМУ, 2014. — С. 28.

11. Насонова, В. А. Ранние диагностика и лечение подагры — научно обоснованное требование улучшения трудового и жизненного прогноза больных / В. А. Насонова, В. Г. Барскова // Науч-практич ревматол. — 2004. — № 1. — С. 5—7.

12. Павлов, В. П. Хирургическое лечение хронической подаг­ ры / В. П. Павлов [и др.] // Научнопрактическая ревматология. — 2000. — № 38. — С. 54—56.

13. Becker, M. A. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: A twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout / M. A. Becker [et al.] // Arthr Rheum. — 2005. — № 52. — P. 916—923.

14. Borstad, G. C. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gout arthritis / G. C. Borstad [et al.] // J Rheumatol. — 2004. — № 31. — P. 2429—2432.

15. Cavagna, L., Taylor W. J. The emerging role of biotech­nological drugs in the treatment of gout / L. Cavagna, W. J. Taylor // Biomed Res Int. — 2014.

16. CHMP post-autorisation summary of positive option for Ilaris. First published 2013.

17. Csaba, A. Dezsi. The different therapeutic choices of ARBs. Which one to give? When? Why? / Csaba, A. Dezsi // American Jour­nal of Cardiovascular Drugs. — 2016. — Vol. 16, Issue 4. — P. 255—266.

18. Dalbeth, N. Effects of skim milk powder enriched with glycomacropeptide and G600 milk fat extract on frequency of gout flares: a proof-of-concept randomised controlled trial / N. Dalbeth [et al.] // Ann Rheum Dis. — 2012. — № 71. — P. 929—934.

19. Dessein, P. H. Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein / P. H. Dessein [et al.] // Ann Rheum Dis. — 2000. — № 59. — P. 539—543.

20. Dinarello С. А. Аn ехрanding role in interleukin-1 blokade from gout to cancer // Моl. Меd. — 2014 Dес 16; 20 suppl 1. — Р. 43—58.

21. Doherty, M. A randomised controlled trial of ibuprofen, paracetamol or a combination tablet of ibuprofen/paracetamol in communityderived people with knee pain / M. Doherty [et al.] // Ann Rheum Dis. — 2011. — № 70. — P. 1534—1541.

22. Hosoya, T. Combined therapy using allopurinol and benz­-bromarone for gout and hyperuricemia complicated with renal disorder / T. Hosoya [ey al.] // Jpn J Rheumatol. — 1992. — P. 77—90.

23. Jordan, K. M. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout / K. M. Jordan [et al.] // Rheumatology (Oxford). — 2007. — № 46. — P. 1372—1374.

24. Khosravan, R. The effect of age and gender on pharma­cokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase / R. Khosravan [et al.] // J Clin Pharmacol. — 2008. — № 48. — P. 1014—1024.

25. Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative / F. Sivera [et al.] // Ann Rheum Dis. — 2014. — № 73. — P. 328—335.26.

26. Neogi, T. Clinical practice. Gout / T. Neogi // J Med. — 2011. — № 364. — P. 443—452.26. Paulus, H. E. Prophylactic col­chicine therapy of intercritical gout a placebo-controlled study of probenecid-treated patients / H. E. Paulus [et al.] // Arthritis Rheum. — 1974. — № 17. — P. 609—614.

27. Perez-Ruiz, F. Effect of urate-lowering therapy on the velo­city of size reduction of tophi in chronic gout / F. Perez-Ruiz [et al.] // Arthritis Rheum. — 2002. — № 47. — P. 356—360.

28. Perez-Ruiz, F. Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout / F. Perez-Ruiz, F. Liote // Arthritis Rheum. — 2007. — № 57. — P. 1324—1328.

29. Perez-Ruiz, F. Treating to target: A strategy to cure gout / F. Perez-Ruiz // Rheumatology (Oxford). — 2009. — № 48. — P. 9—14.

30. Sarawate, C. A. Serum urate levels and gout flares: Analysis from managed care data / C. A. Sarawate [et al.] // J Clin Rheumatol. — 2006. — № 12. — P. 61—5.

31. Schlesinger, N. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two rando­mised, multicenter, active-controlled, double-blind trials and their initial extentions / N. Schlesinger, R. E. Alten, T. Bardin // Ann Rheum Dis. — 2012. — V. 71 (11). — P. 1839—1848.

32. Schlesinger, N. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study / N. Schlesinger [et al.] // Ann Rheum Dis. — 2011. — № 70. — P. 1264—1271.

33. Schumacher, H. R. Febuxostat vs allopurinol and placebo in subjects with hyperuricemia and gout: the 28-week APEX study / H. R. Schumacher [et al.] // Arthr Rheum. — 2005. — № 52. — P. 680.

34. Schumacher, H. R. The FOCUS trial 48-month interim ana­lysis: long-term clinical outcomes of treatment with febuxostat in subjects with gout in an ongoing phase 2, open-label extension study / H. R. Schumacher [et al.] // Ann Rheum Dis. — 2006. — № 65. — P. 93.

35. Schumacher H. R. Randomised double blind trial of eto­ricoxib and indometacin in treatment of acute gouty arthritis / H. R. Schumacher [et al.] // BMJ. — 2002. — № 324. — P. 1488—92.

36. Schumacher, H. R. Rilonacept (IL-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: Results of a phase 2 clinical trial / H. R. Schumacher [et al.] // Arth­ ritis Rheum. — 2012. — Vol. 64 (3). — P. 876—884.

37. Sо, А. A pilot study of IL-1 inhibitor by anakinra in acuta gout / А. Sо [et al.] // Arthritis Res. Ther. — 2007. — Vоl. 9 (2). — Р. 28.

38. Sо, А. Canakinumab for the treatment of acute flares of difficult-to-treat gouty arthritis: Results of multicenter, phase II, dose-ranging study / А. Sо [еt а1.] // Аrthritis Rheum. — 2010. — Vol. 62 (10). — Р. 3064—76.

39. Stamp, L. K. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment / L. K. Stamp [et al.] // Arthritis Rheum. — 2011. — № 63. — P. 412—21.

40. Rubin, B. R. et al. Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial / B. R. Rubin [et al.] // Arthr Rheum. — 2004. — № 50. — P. 598—606.41.

41. Теrkeltaub L. The interleukin-1 inhibitor rilonacept in treat­ment of chronic gouty arthritis / L. Теrkeltaub [et al.] // Ann Rheum Dis. — 2009. — Vоl. 68. — Р. 1613—7.

42. Thanassoulis, G. Gout, allopurinol use, and heart failure outcomes / G. Thanassoulis [et al.] // Arch Int Med. — 2010. — № 170. — P. 1358—64.

43. Trelle, S. Cardiovascular safety of non-steroidal anti-inflam­matory drugs: network meta-analysis / S. Trelle [et al.] // BMJ. — 2011. — № 342. — P. 7086.

44. Vazquez-Mellado, J. Relation between adverse events as­sociated with allopurinol and renal function in patients with gout / J. Vazquez-Mellado [et al.] // Ann Rheum Dis. — 2001. — № 60. — P. 981—983.

45. Wortmann, R. L. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: Analysis of data from three phase III trials / R. L. Wortmann [et al.] // Clin Ther. — 2010. — № 32. — P. 2386—2397.

46. Zhang, W. EULAR evidence based recommendations for gout. Part II: Management. Report of a Task Force of the EULAR Standing Committee for international clinical studies including the­ rapeutics (ESCISIT) / W. Zhang [et al.] // Ann Rheum Dis. — 2006. — № 65. — P. 1312—1324.